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Introduction: To evaluate prognostic factors of thymic epithelial 
tumors (TETs) with particular reference to histology and the dose–
response relationship of adjuvant radiotherapy.
Methods: Retrospective study with central pathological review 
on patients resected for TET between 1966 and 2004 at a single 
institution. Prognostic factors were identified using Cox regression 
analysis.
Results: From 93 patients with TET, 33.3% relapsed and 47.3% 
died. Cause of death was known in 64% and attributed to TET in 
25%. Myasthenia gravis was associated with superior disease-free 
survival (DFS) and overall survival (OS). Tumors smaller than 
8.5 cm had a significantly better prognosis. With a median follow-up 
of 9.8 years actuarial OS at 5, 10, and 20 years were 96%, 92%, and 
47% in stage I; 85%, 61%, and 53% in stage II; 72%, 39%, and 15% 
in stage III and IV. Advanced stage and incomplete resection had 
a negative impact on DFS and OS. According to histology (WHO 
type A, AB, B1; favorable; versus WHO type B2, B3; intermedi-
ate; versus thymic carcinoma , unfavorable) three prognostic groups 
were discernible. On multivariate analysis, tumor size, and stage 
emerged as prognostic factors, but neither histology nor myasthenia. 
Postoperative radiotherapy was administered in 27 patients (median 
dose 50.8 Gy). Doses in excess of 50 Gy were associated with sig-
nificantly improved DFS and OS.
Conclusions: Tumor stage, histology, complete resection, and tumor 
size had a significant impact on survival. Myasthenia may facili-
tate early detection and is correlated with superior survival. When 
postoperative radiotherapy is administered, doses above 50 Gy may 
improve outcome.
Key Words: Radiotherapy, Adjuvant thymoma/pathology, Myasthenia 
gravis, Multivariate analysis, Retrospective studies, Thymic epithelial 
tumors, Radiotherapy, Dose.
(J Thorac Oncol. 2012;7: 1867–1871)
Thymic epithelial tumors (TETs) are rare neoplasms aris-ing from the epithelial component of the thymus. They are 
usually located in the anterior mediastinum. Many TETs take 
an indolent clinical course and are often incidentally detected 
by unrelated diagnostics (computed tomography scan) or 
during the diagnostic workup of paraneoplastic syndromes, 
in particular myasthenia gravis (MG). Other thymomas and 
the consistently aggressive thymic carcinomas may present 
with clinical symptoms or other local complications. Men 
and women are almost equally affected, but a slight male pre-
ponderance has been noted.1 Because TETs are rare tumors 
with an incidence of 0.15 per 1,00,000 person years,1 most 
published data come from retrospective cohort studies and 
occasional prospective studies. Randomized trials are lacking. 
Multiple inconsistencies between studies related to important 
variables including length of follow-up and tumor histologic 
classification hamper definite treatment recommendations. In 
particular, the role of adjuvant radiotherapy and the required 
dose are controversially debated.2
MATERIALS AND METHODS
In this retrospective analysis, files of patients operated 
on between 1966 and 2004 for TET at Heinrich-Heine-
University hospital at Duesseldorf, Germany, were retrieved 
from the archives of Heinrich-Heine-University. The surgical 
logs were screened for any thymic or mediastinal tumor if not 
otherwise unambiguously specified as nonthymic tumor. The 
medical records including histology reports, surgical reports, 
and follow-up entries were scrutinized. If diagnosis of TET 
was approved, patients were enrolled onto the study. Diagnoses 
were subject to a central pathological review by expert 
pathologists (AM, PS) if histological slides were amenable. 
Survival information was extracted from the medical records 
if available. Otherwise, actual survival data were obtained by 
telephone or by inquiry to the referring physicians and local 
residents’ registries.
Survival data were counted from surgery to diagnosis of 
relapse or death. Median survival rates were calculated using 
the product-limit estimate of the Kaplan–Meier method, and 
the log-rank test was used to compare the group difference in 
survival function. Cox proportional hazards models were used 
in evaluation of differences for disease-free survival (DFS) 
and overall survival (OS). Statistical analyses were performed 
with Statistical Analysis Software (SAS Institute, Cary, NC). 
Univariate analyses were restricted to a set of general or 
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thymic-specific prognostic variables, that is, dyspnea, MG, 
Masaoka’s stage (stage I versus stage II versus stage III or 
IV), and World Health Organization (WHO) histological clas-
sification (A, AB, or B1 versus B2-3 versus thymic carcinoma 
[TC]; B2 versus B3). If a given tumor showed components 
of different histological WHO subtypes (combined TET), it 
was classified according to the supposedly most aggressive 
component.3,4 In repeat analyses, p values were corrected for 
multiple tests (Bonferroni method).
RESULTS
Between 1966 and 2004, 95 patients were treated for 
TET s. Because of revised histology, two patients were to be 
excluded (revised diagnoses were Castleman’s disease and 
malignant lymphoma, respectively). The eligible 93 patients 
constitute the study population (Table 1). The median age was 
50.6 years (range, 14–79). During follow-up (mean 9.8 years, 
range, 1 month–34 years) 31 patients (33.3%) relapsed and 44 
patients (47.3%) died. The median period from diagnosis to 
relapse was 5.6 years. The cause of death (Table 2) is known 
in 28 patients (64%), with 11 deaths (25%) attributable to thy-
moma and five deaths because of second malignancies. Among 
12 patients who experienced a second malignancy, colorectal 
cancer (n = 4) and breast cancer (n = 3) were the leading diag-
noses. Two patients died of MG. The remaining 10 patients 
died of various TET-unrelated and nonmalignant diseases.
Most TETs were found incidentally. Forty-two percent 
patients suffered from complaints, mostly from dyspnea, chest 
constriction and pain, or cough. Autoimmune diseases were 
present in 44%, with MG being the most common diagno-
sis. Patients with MG had smaller tumors (6 cm) than patients 
without myasthenia (mean 10 cm). Moreover, DFS (p = 0.077) 
and OS (p = 0.0095) were superior if myasthenia was pres-
ent. Tumor size ranged from 1.0 to 20.0 cm (median 8.5 cm). 
A diameter greater than 8.5 cm was associated with a signifi-
cantly lower relapse-free survival and OS (p < 0.0001).
In 91 patients, the stage was known (Table 3). Of these 
patients, 28 (30%), 29 (31%), 29 (31%), and 5 (5%) were 
found with Masaoka stage I (capsule not invaded), II (invasion 
of mediastinal fat or pleura), III (invasion of the pericardium, 
great vessels), and IV (metastatic disease), respectively. The 
corresponding 5-, 10-, and 20-year actuarial OS rates were 
96%, 92%, and 47% in stage I; 85%, 61%, and 53% in stage 
II; 72%, 39%, and 15% in stages III and IV. The correspond-
ing DFS rates are shown in Fig. 1. Masaoka stage had a sig-
nificant impact on both, DFS (p < 0.0001) and OS (p < 0.002).
Surgical margins were assessable in 38 patients (41 %). 
In particular, early pathology reports were lacking in details 
on resection status. Complete resection (R0) was diagnosed 
in 14 patients, microscopically involved margins (R1) in 
18 patients, and incomplete resection (R2) in six patients. 
Survival rates for 5 and ten years were 84% and 64% (R0), 
respectively, 100% and 100% (R1), respectively, and 33% 
and 16% (R2), respectively. The impact of incomplete macro-
scopic resection was significant on both, DFS (p = 0.047) and 
OS as well (p = 0.017).
Three histological groups were compared according 
to previous studies.4,5 Group I comprising WHO type A, AB, 
and B1; group II WHO type B2 and B3; and group III TC. 
In case of combined TETs, the histological classification of 




Surgery alone 53 57.0
Surgery and postoperative radiotherapy 27 29.0
Surgery and chemoradiation 4 4.3
Surgery and chemotherapy 3 3.2
Aadjuvant therapy not accessible 6 6.5
TABLE 2.  Cause of Death
Deaths 44 47.3 % of Study Population
Attributed to thymoma 11 25
Second malignancies 5 11.4
Surgical mortality 2 4.5
Attributed to myasthenia 2 4.5
Other (unrelated to thymoma) 8 18.2
Unknown 16 36.4








Available SumI II III IVa IVb
A 6 4 0 0 0 0 10
AB 9 4 2 0 0 0 15
B1 3 2 3 0 0 0 8
B2 2 7 4 1 0 0 14
B3 1 2 2 0 1 0 6
Thymic carcinoma 1 3 9 0 0 1 14
B1 + B2 2 1 0 0 0 0 3
B2 + B3 1 3 7 2 0 0 13
B3 + thymic carcinoma 0 1 0 0 0 0 1
Not classified 3 2 2 0 1 1 9
Sum 28 29 29 3 2 2 93
WHO histologic type A; AB; B1; B2; B3; thymic carcinoma.
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assignment. The OS rates at 5 years according to group I, II, 
and III (87.1%,88.3%, and 60.0%), 10 years (63.9%, 72.2%, 
and 37.5%), and 20 years (39.1%, 48.7%, and 11.3%) did not 
differ between group I and group II, but OS in group III was 
significantly worse (p = 0.006). With regard to DFS (Fig. 2) all 
three groups were significantly different (p ≤ 0.0001). OS (p = 
0.85) and DFS (p = 0.66) did not differ significantly between 
WHO type B2 and B3.
In Cox regression analysis, tumor size less than 8.5cm 
(p = 0.045) and Masaoka stage lower than III (p = 0.0011) 
emerged as independent favorable prognostic factors. 
Histology did not prove to be independently significant in 
multivariate analysis nor did myasthenia (Table 4).
Postoperative radiotherapy was administered in 27 
patients (two in stage I, 12 in stage II, 12 in stage III, and 
one in stage IV). In 22 patients the applied radiation dose 
was documented (range, 38.5–57.6 Gy; median 50.8 Gy). 
We noted a dose–response relationship. In doses in excess of 
50 Gy as compared with doses lower than 50 Gy, both DFS 
(Fig. 3, p < 0.0025) and OS (p < 0.005) significantly improved 
with the higher dose.
DISCUSSION
Thymomas and thymic carcinomas, also referred to as 
TETs, are malignant tumors arising from thymic epithelium. 
Many slow-growing thymomas typically take an indolent 
course and have a fair prognosis. However, misleading terms 
such as benign thymomas have been abandoned because TETs 
harbor a distinct, though highly variable, malignant potential. 
Local recurrence is by far more common than distant metasta-
ses. Lymph node metastases are particularly rare (0%–2.4%).6 
Late manifestations of recurrence are characteristic,7 as 
confirmed in our study (1–17.9 years, average 5.6 years in our 
study). Therefore, an extended follow-up (9.8 years mean in 
our study) is mandatory in these slow-growing tumors.8
Recently, the WHO revised the histopathologic 
classification of thymomas.9 On the basis of studies by Muller-
Hermelink and coworkers,10,11 TET were assigned to six 
categories with regard to the morphology of epithelial cells 
and the lymphocyte to epithelial cell ratio, that is, thymoma 
types A, AB, B1, B2, and B3 and TC. This classification has 
been widely adopted. Several reports have discussed the 
reproducibility and prognostic value of the WHO system.12,13 
Generally, type A, AB, and B1 thymomas take a favorable 
course with 5- and 10-year OS rates between 80% and 100%14 
whereas B2 and, in particular, B3 thymomas were generally 
found to be more aggressive with early pleural dissemination 
and a low but distinct potential to metastasize.15 TETs having 
both, B2 and B3, features are common and form a continuum 
rather than distinct entities.16,17 The prognostic importance of 
histology has been shown in several studies.18,19 In a recent 
meta-analysis based on 2192 patients in 15 studies, three 
groups combining different histological subtypes (A/AB/
B1, B2, and B3) separated different prognostic groups.20 In 
our study three WHO-histology based groups comprising 
type A, AB, and B1 versus type B2 and B3 versus TC were 
prognostic for DFS (p ≤ 0.0001). In regard to OS, only 
TC differed significantly from other histological groups 
(p = 0.006). In contrast to Marchevsky et al.20 we found no 
different prognosis between B2 and B3 thymomas, but this 
discrepancy might be because of the small number of B2 and 
B3 cases in the current study. However, our data support the 
findings of other investigators4,5,21 that type A, AB, and B1 
thymomas constitute a particularly low risk group of TETs. 
Consequently, adjuvant radiotherapy may be omitted in these 
patients.22
Stage is the most recognized prognostic factor in TET. 
In patients with stage I/II disease recurrence is extremely 
uncommon.23 Transcapsular invasion discriminates stage I 
from II, but it is uncertain whether this distinction is actu-
ally significant with regard to prognosis.24 The 10-year DFS 
of thymoma is 92% in stage I, 87% in stage II, and 60% in 
stage III.25 We observed similar favorable survival rates at 5 
years in stage I (96%) and II (85%) as opposed to stage III 
(72%). On Cox regression analysis, tumor size and Masaoka 




Variable p Hazards Ratio
Confidence 
Interval
Tumor size < 8.5 cm 0.0447 2.178 1.048 4.804
Stage < III 0.0011 3.639 1.418 10.449
Histology thymic carcinoma 0.9539 0.975 0.396 2.413
Histology WHO B2 & WHO B3 0.4549 0.726 0.273 1.884
Myasthenia gravis 0.0868 0.457 0.163 1.190
KI, ; WHO, World Health Organization.
FIGURE 3.  Disease-free survival according to applied dose 
(p = 0.0025)
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stage, but not histology, were found to be independent prog-
nostic factors. At least, in part, this may reflect an interrelation 
between histology and Masaoka stage, that is, invasiveness.5 
Although macroscopic complete resection was associated 
with an excellent survival rate irrespective of the margin sta-
tus (R0 or R1), macroscopic residual tumor was associated 
with poor outcome.
Approximately 25% of the thymomas were present with 
MG.26 Early studies27 consistently reported an inferior prog-
nosis with MG. In contrast, we observed an even superior 
survival if myasthenia was present. Myasthenia presumably 
facilitates early diagnosis, as we also found the median tumor 
size was considerably less when myasthenia was present.
TET is sensitive to radiation.28 The predominant sites 
of recurrence are the lung, pleura, and diaphragm.2 Hence it 
is reasonable that local radiation therapy (RT) might decrease 
recurrence rates and ultimately improve survival. Randomized 
trials are lacking. In the past, some authors advocated 
postoperative radiotherapy for all TET patients, irrespective of 
stage.29 However, there is no firm evidence that radiotheraphy 
for stage I/II patients after complete resection may further 
improve the excellent outcome.30–33 Traditionally, advanced 
stage and residual disease were the most important reasons to 
give postoperative radiotherapy. It is widely considered standard 
of care for stage III/IV TET after complete and incomplete 
resection.34 Radiotherapy may also reduce the risk of local 
recurrence in patients with residual macroscopic disease.35–37 
However, the identification of patients at high risk of local 
recurrence who require adjuvant therapy remains controversial. 
A recent analysis of the Surveillance, Epidemiology and 
End Resultsregistry data found postoperative radiotherapy 
beneficial in regional disease as opposed to local disease.31 
However, in a recent meta-analysis firm conclusions regarding 
the utility of adjuvant radiotherapy could not be derived in 
either stage II or stage III.2 After complete resection most 
studies recommend doses from 45 to 55 Gy in daily fractions 
of 1.8 to 2.0 Gy. However, a dose–response relationship 
has not been established.38,39 Some considered 40 Gy to be 
sufficient40 whereas others suggested higher doses.41 We 
observed a significant benefit in regard to both, DFS and OS 
with postoperative radiotherapy exceeding 50 Gy. Because 
of the retrospective nature of this study and the extended 
follow-up, these results may be biased by many potential factors 
such as patient selection and advances in radiotherapy.
There is an approximately three-to-four times’ in creased 
risk of second malignancies in thymoma patients.42,43 Con sid-
ering the common long-term course of thymoma radiation-
induced malignancies must be taken into account. To observe 
radiation-induced cancer a prolonged follow-up is mandatory, 
such as 9.8 years in the present study. Analyzing the popula-
tion-based Surveillance, Epidemiology and End Results data, 
the incidence of secondary malignancies was 9% in patients 
with thymoma, corresponding to an excess risk of 50%. This 
finding is in line with our findings of 13% second malignancies. 
However, the most frequent second cancer (colorectal cancer) 
arose outside the radiation portals. Although breast cancer may 
potentially induced by radiation, no lung cancer (same treat-
ment volume) was observed in the irradiated patients.
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